Keywords

Chemotherapy, Exploratory factor analysis, Ovarian neoplasms, Symptom clusters, Symptoms, Uterine neoplasms

 

Authors

  1. Pozzar, Rachel A. PhD, RN
  2. Hammer, Marilyn J. PhD, RN
  3. Cooper, Bruce A. PhD
  4. Kober, Kord M. PhD
  5. Chen, Lee-May MD
  6. Paul, Steven M. PhD
  7. Conley, Yvette P. PhD
  8. Cartwright, Frances PhD, RN
  9. Wright, Fay PhD, RN
  10. Levine, Jon D. MD, PhD
  11. Miaskowski, Christine PhD, RN

Abstract

Background: Patients with gynecologic cancer undergoing chemotherapy experience multiple co-occurring symptoms. Understanding how symptom clusters change over time is essential to the development of interventions that target multiple co-occurring symptoms.

 

Objective: The aim of this study was to assess the relative stability of symptom clusters across a chemotherapy cycle in patients with gynecologic cancer.

 

Methods: This is a longitudinal, descriptive study. Eligible patients (n = 232) were English-speaking adults (>=18 years old) with gynecologic cancer. Data were collected in the week before patients' second or third cycle of chemotherapy (T1) and at 1 (T2) and 2 (T3) weeks after chemotherapy. Three dimensions of the symptom experience (occurrence, severity, and distress) were assessed using a modified version of the Memorial Symptom Assessment Scale. Symptom clusters for each dimension and time point were identified through exploratory factor analysis.

 

Results: A 5-factor solution was selected for each exploratory factor analysis. Hormonal, respiratory, and weight change clusters were identified across all dimensions and time points. A psychological symptom cluster was identified at T1 for occurrence and severity and at T2 and T3 for all 3 dimensions. A gastrointestinal symptom cluster was identified at T1 for occurrence and at T2 and T3 for all 3 dimensions. The hormonal, respiratory, psychological, and weight change symptom clusters exhibited common symptoms across dimensions and time points.

 

Conclusions: Hormonal, respiratory, weight change, and psychological symptom clusters are relatively stable across a cycle of chemotherapy in patients with gynecologic cancer.

 

Implications for Practice: Clinicians need to assess patients for multiple co-occurring symptoms and initiate multimodal interventions.